Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for ALKEM
Revenue projections for ALKEM

ALKEM's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 2.55300
forwardPE 23.96355
debtToEquity 14.26700
earningsGrowth -0.22700
revenueGrowth 0.14600
grossMargins 0.65384
operatingMargins 0.11424
trailingEps 192.59000
forwardEps 226.38548

ALKEM's current ratio of 2.553 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that ALKEM is financially well-prepared to meet its liabilities without difficulty.
With Alkem Laboratories Limited's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
ALKEM's low Debt-to-Equity ratio highlights its minimal reliance on debt, showing that the company is not over-leveraged. This contributes to lower financial risk and greater stability, giving ALKEM a stronger position in managing its financial obligations.
ALKEM's low earnings and revenue growth suggest that the company may see declining profits. This indicates potential financial challenges ahead, and could lead to a more cautious outlook from investors.
ALKEM's negative gross and operating margins indicate that the company is unprofitable, struggling to cover its production and operational costs. This reflects potential weaknesses in cost management or declining sales performance.
ALKEM's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.

Price projections:

Price projections for ALKEM
Price projections for ALKEM

Throughout its recent performance, ALKEM's price has been consistently close to the lower range of projected values. This suggests that the company may face challenges in achieving higher valuations in the eyes of investors.

Recommendation changes over time:

Recommendations trend for ALKEM
Recommendations trend for ALKEM


Analysts have shown a buy bias for ALKEM, marking it as a favorable investment option. This could inspire investors to see ALKEM as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.